The gist: Combining existing drugs can sometimes result in new, more effective cancer treatments. As we posted on our Need to Know blog today, lung cancer researchers are testing drug combinations that involve immunotherapies—treatments that boost the immune system to fight cancer. Now, two drug companies have announced that they will be testing combinations of their lung cancer drugs. An immunotherapy drug called Opdivo will be combined with targeted drugs. The combinations will be tested in clinical trials with volunteer patients who have late-stage non-small cell lung cancer (NSCLC). It is hoped that the combinations will work better than any of the drugs alone.
“Swiss pharma group Novartis AG said on Monday it would work with Bristol-Myers Squibb Co to test the U.S. drugmaker’s immuno-oncology drug Opdivo in combination with three of its own experimental lung cancer drugs.
“The clinical collaboration will help Novartis advance its efforts in the field of immunotherapy, one of the hottest areas in biotech right now, following the acquisition of CoStim Pharmaceuticals Inc this year, the drugmaker said.
“Novartis currently lags rivals such as Roche, Merck , AstraZeneca and Bristol-Myers in the race to develop immunotherapies – drugs that fight cancer by harnessing the body’s immune system.
“The two companies will test the combination of three molecularly targeted compounds with Bristol-Myers’ investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in phase I and II studies, Novartis said, adding it would conduct both studies.
” ‘Preclinical data suggests that combining molecularly targeted agents with immunotherapies such as nivolumab may have synergistic effects and lead to better outcomes for patients,’ Alessandro Riva, global head of Novartis oncology development and medical affairs, said in the statement.”
The gist: A new immunotherapy drug called Opdivo has shown promising results for melanoma patients in a clinical trial—a research study with volunteer patients.
“Bristol-Myers Squibb’s immunotherapy drug Opdivo produced markedly improved response rates with fewer toxic side effects compared to chemotherapy in a major melanoma study, underscoring its potential as a new treatment option.
“The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body’s own immune system fight cancer.
“In the study, involving people with advanced melanoma, 32 percent of patients saw their tumours shrink when given Opdivo against 11 percent of those treated with conventional chemotherapy drugs.”
Editor’s note: Two large drug companies are teaming up to combine their drugs to fight breast cancer, pancreatic cancer, and lung cancer. The two drugs are nivolumab (Opdivo) and nab-paclitaxel (Abraxane). The companies will enroll volunteer patients in clinical trials to test how effective the combo is.
“Bristol-Myers Squibb’s determination to get its Opdivo immunotherapy into the U.S. market as a cancer medication took a new turn Wednesday. The firm said it is teaming with biotechnology giant Celgene Corp. to develop a treatment to fight certain types of tumors using the drug.
“The plan is for Bristol-Myers BMY to try and combine its immunotherapy treatment with Celgene’s CELG chemotherapy drug Abraxane in clinical trials with patients suffering from certain types of cancer of the breast, pancreas and lungs.
“Bristol-Myers and Celgene are examining to see whether the combination of the two drugs will produce a stronger tumor combatant than either drug acting alone.”
Editor’s note: Opdivo (aka nivolumab) is a drug that has shown promise for treating advanced melanoma in clinical trials with volunteer patients. The company that makes Opdivo, Bristol-Myers Squibb, has submitted an application to the U.S. Food and Drug Administration (FDA) that, if approved, would allow the company to market Opdivo to patients in the U.S. Opdivo is an immunotherapy treatment, meaning that it boosts a patient’s own immune system to fight cancer. Immunotherapies are a promising area of melanoma research, as described by our Chief Scientists on our Need to Know blog.
“Bristol-Myers Squibb Co said on Thursday it plans to seek U.S. marketing approval in the third quarter for its experimental cancer immunotherapy Opdivo as a treatment for advanced melanoma, which would be months sooner than Wall Street expected.
“The company said it would seek approval to market the drug to patients who had previously been treated with Bristol-Myers’ already approved melanoma drug Yervoy, which works through a different mechanism than Opdivo…
“Opdivo works by blocking a protein called PD-1, thereby enabling the immune system to recognize cancer cells and then attack them. It is considered one of Bristol-Myers’ most important experimental drugs, with potential to generate multibillion-dollar annual sales, if approved.”